Armis Named a Leader in 2025 Gartner® Magic Quadrant™ for CPS Protection Platforms
Armis supports global enterprises’ vast and varied needs to effectively secure critical CPS environments
Armis, the cyber exposure management & security company, today announced that it has been named a Leader in the 2025 Gartner Magic Quadrant for CPS Protection Platforms.
Cyber-physical system environments connect the physical and digital worlds, supporting sectors including infrastructure, transportation, healthcare and smart manufacturing. Their growing role increases risk due to complex IT, OT, IoT, and IIoT integrations that need robust security. We believe the Gartner Magic Quadrant for CPS Protection Platforms highlights the importance of protecting these systems.
“Attacks on cyber-physical systems can disrupt operations and endanger lives, making their security our core mission, driven by innovation, expertise and customer collaboration,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “We believe being named a Leader in this report is a testament to the support that we provide and the partnerships that we have with our customers as part of our unwavering commitment to redefining and advancing the security of cyber-physical systems. We will continue to innovate to protect society as we know it from the attacks of cybercriminals and nation-state adversaries who aim to cause disruption and harm.”
Armis was named a Leader within this report among the 17 vendors that were evaluated. Armis Centrix™, the Armis Cyber Exposure Management Platform, was positioned within the report for its Completeness of Vision and Ability to Execute.
As of February 11, 2025, Armis had 28 reviews on Gartner Peer Insights™ in the CPS Protection Platform category with an overall rating of 4.7 out of 5. Read customers’ praises of Armis’ CPS Protection Platform solution through verified ratings and reviews on Gartner® Peer Insights here and below:
- “Support for this product is by far the best I've encountered out of any product I use here. The usefulness of this product is pivotal for visibility of devices on our network.” - Manager, IT Security and Risk Management (Industry: Manufacturing)
- “Armis provides the Cybersecurity team with what it needs seamlessly. It helps us manage our assets, identify and resolve vulnerabilities faster, and helps us make better decisions on our security policy. Our customer success manager has always made himself available to us, which is key in being able to understand Armis' capabilities and how it benefits our organization.” - Cybersecurity Administrator (Industry: Government)
- “The company does a phenomenal job at listening to our questions/concerns and implementing a solution. They are truly customer focused.” - IT Security & Risk Management Associate (Industry: Healthcare and Biotech)
- "We had a positive experience with the vendor. Their team was consistently professional, prepared, and responsive. They also had initiatives for different use cases that were off our list initially. They demonstrated a strong understanding of the solution and the industry. Overall, the service was reliable and met our expectations well.” - Manager, IT Security (Industry: Retail)
- “Great experience. We have added a ton of visibility in our environment.” - IT Security & Risk Management Associate (Industry: Healthcare and BioTech)
Read our blog to learn more about why Armis was named a Leader in the 2025 Gartner® Magic Quadrant for CPS Protection Platforms.
Find more information about Armis Centrix™, the cyber exposure management platform, here.
For additional analyst reports recognizing Armis, please visit our Analyst Relations webpage.
Gartner Disclaimer
Gartner, Magic Quadrant for CPS Protection Platforms, Katell Thielemann, Wam Voster, Ruggero Contu, 12 February 2025.
Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT and PEER INSIGHTS is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
About Armis
Armis, the cyber exposure management & security company, protects the entire attack surface and manages the organization’s cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets – from the ground to the cloud. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218934891/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Unveils New Post-Hoc Analyses of LIBERTY Studies at the 20th ECCO Congress Further Evaluating the Efficacy and Safety of Subcutaneous (SC) Infliximab20.2.2025 17:45:00 CET | Press release
Post-hoc analyses at ECCO 2025 build on pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) which has previously demonstrated superior efficacy of subcutaneous (SC) infliximab (CT-P13 SC) over placebo in moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC)1,2New data highlights the effectiveness of SC infliximab in achieving endoscopic-histologic remission in UC and clinical and endoscopic improvement in CD across all disease locations3,4Further insights on rapid clinical recapture following dose escalation of SC infliximab after loss of response and long-term drug persistence in CD regardless of anti-drug antibodies (ADA) occurrence highlights the robustness of SC infliximab in IBD management5,6 Celltrion announced new post-hoc analyses of its pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), at the 20th European Crohn’s and Colitis Organisation (ECCO) Congress showcasing the treatment’s effectiveness across a range of key clinical outcomes in inflammatory
NTT DATA Launches Smart AI Agent™ to Accelerate Generative AI Adoption and Drive $2 Billion in Revenue by 202720.2.2025 16:33:00 CET | Press release
Next-generation AI tool will enhance operational efficiency, address global talent shortages, and empower businesses with smarter automation. NTT DATA, a global digital business and IT services leader, today announced the international launch of its next-generation Smart AI Agent™. This advanced AI tool is a cornerstone of the company’s strategy to accelerate the adoption of Generative AI, with an estimated $2 billion in revenue that we aim to achieve from Smart AI Agent™-related business by 2027. The Smart AI Agent™ autonomously extracts, organizes, and executes tasks in response to user instructions, complementing existing workforces and streamlining time-consuming processes. By enhancing efficiency across industries, the Smart AI Agent™ enables businesses to rapidly evaluate and deploy Generative AI applications, optimizing workflows and driving greater productivity. Yutaka Sasaki, President and CEO, NTT DATA, said: “The launch of our Smart AI Agent™ is a direct response to the grow
New global guideline published on managing fungal infections caused by Candida20.2.2025 16:15:00 CET | Press release
For Trade and Medical Media Only A new global guideline for the diagnosis and treatment of Candidainfections was recently published in Lancet Infectious Diseases1. This guideline sets out new standards for managing fungal infections, which affect millions of people worldwide every year. The global guideline was developed by a team of more than 100 experts spanning 35 countries and led by Professor Dr. Oliver A. Cornely and Dr. Rosanne Sprute from University Hospital Cologne. One year following the European Medical Association (EMA)2 approval, rezafungin ▼3 has been included in the guideline, along with other echinocandins, as a strongly recommended first line therapy option for the treatment of candidaemia. Echinocandins, including rezafungin, are preferred for all forms of invasive candidiasis, excluding CNS and ocular infections, due to their broad antifungal activity and favourable safety profile. The new guideline, which took four years to develop, contains recommendations for clin
SiMa.ai and HTEC Strengthen Strategic Partnership to Advance Premium ML System-on-Chip Solutions20.2.2025 16:08:00 CET | Press release
HTEC, a global digital engineering services firm, is pleased to announce a partnership extension with SiMa.ai, the software-centric, embedded edge machine learning system-on-chip (MLSoC) company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250220864540/en/ HTEC announces partnership extension with SiMa.ai, an embedded edge machine learning system-on-chip company. (Graphic: Business Wire) During a successful five-year collaboration, SiMa.ai and HTEC built an ML compiler, system drivers, and other complex AI-powered software tools to support SiMa.ai’s edge AI platform. SiMa.ai also leveraged HTEC’s AI- and ML-driven engineering and chip optimization expertise to enhance its purpose-built MLSoC™. Now, HTEC will support SiMa.ai’s strategic initiatives and help streamline the delivery of SiMa.ai solutions built on its cutting-edge ONE Platform for Edge AI, further enhancing the company’s hardware and software. “Collaborating w
ClickHouse Announces BYOC (Bring Your Own Cloud) on AWS20.2.2025 15:00:00 CET | Press release
Bringing the power of the fastest real-time analytical database to customer VPCs As enterprises look to modernize and adopt cloud-native architectures, they must still comply with existing security mandates and geographic regulations. This becomes especially challenging with cloud-based database services, where any data leaving the enterprise Virtual Private Cloud (VPC) requires thorough security review. These considerations are critical for organizations in regulated industries or those handling sensitive customer data. ClickHouse BYOC was built to address this very challenge. It allows organizations to adopt unique capabilities of the fully-managed ClickHouse Cloud service, a leading real-time analytical database, while maintaining full ownership and control of their data within their VPC. In ClickHouse BYOC architecture, the data plane consisting of storage and compute resources resides in the customer VPC, which ensures that customers are able to adhere to data residency and govern
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom